Modality
Peptide
MOA
PRMT5i
Target
HER2
Pathway
Wnt
SLEFabryNB
Development Pipeline
Preclinical
~Aug 2019
→ ~Nov 2020
Phase 1
~Feb 2021
→ ~May 2022
Phase 2
~Aug 2022
→ ~Nov 2023
Phase 3
Feb 2024
→ Feb 2026
Phase 3Current
NCT03459441
2,213 pts·NB
2024-02→2026-02·Recruiting
2,213 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-02-022mo agoPh3 Readout· NB
Trial Timeline
Q2Q3Q42025Q2Q3Q42026
P3
Recruit…
Catalysts
Ph3 Readout
2026-02-02 · 2mo ago
NB
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03459441 | Phase 3 | NB | Recruiting | 2213 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C |